ESMO Immuno-Oncology 2025 | Highlighting the role of HPV vaccines in precenting HPV-associated cancers
Amanda Psyrri, MD, PhD, FACP, National Kapodistrian University of Athens, Athens, Greece, emphasizes the importance of adopting preventive HPV vaccines for the prevention of HPV-associated cancers. They are effective at not only against cervical cancer, but also against HPV-associated oropharyngeal cancer, particularly those caused by HPV subtypes 16 and 18, which are covered by the vaccine. Prevention with vaccines is, therefore, crucial in this context. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a very important question. So in terms of the HPV-associated or apparent cancer, for prevention, it’s very essential to adopt the preventive HPV vaccines. So prevention with the vaccines is very important. And vaccines are not effective only for cervical cancer. They are effective also for HPV-associated oropharyngeal cancer because in the vast majority of the cases, HPV-associated oropharyngeal cancer is caused by HPV 16 and 18, especially 16...
This is a very important question. So in terms of the HPV-associated or apparent cancer, for prevention, it’s very essential to adopt the preventive HPV vaccines. So prevention with the vaccines is very important. And vaccines are not effective only for cervical cancer. They are effective also for HPV-associated oropharyngeal cancer because in the vast majority of the cases, HPV-associated oropharyngeal cancer is caused by HPV 16 and 18, especially 16. And these HPV subtypes are covered by the vaccine.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
